{
    "nctId": "NCT02906943",
    "briefTitle": "Ontario-wide Cancer TArgeted Nucleic Acid Evaluation",
    "officialTitle": "Ontario-wide Cancer TArgeted Nucleic Acid Evaluation",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Gynecological Cancer, Genitourinary Cancer, Pancreatobiliary Cancer, Gastrointestinal Cancer, Head and Neck Cancer, Rare Cancer, Unknown Primary Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 10000,
    "primaryOutcomeMeasure": "Number of patients included in a province-wide registry of NGS panel-based testing results",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients with histological confirmation of advanced solid tumor malignancies who are candidates for systemic therapy.\n2. All patients must have sufficient FFPE archived tumor tissue for molecular profiling.\n3. Patient must be \u2265 18 years old.\n4. Patient's ECOG performance status equal to 0 or 1.\n5. All patients must have a life expectancy of \\> 6 months.\n6. All patients must have adequate organ functions.\n7. All patients must have signed and dated an informed consent form.\n\nExclusion Criteria:\n\n1. Patients must not have received more than 2 lines of prior cytotoxic therapy for their recurrent/metastatic disease, with the exception of Phase I trial candidates who will not be excluded if more than 2 lines of prior cytotoxic therapy have been received.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}